Cargando…
Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis
There is a paucity of evidence surrounding the optimal antifungal therapy for use in chronic pulmonary aspergillosis (CPA) and the duration of therapy remains unclear. We retrospectively evaluated treatment outcomes, including change in quality of life scores (St George’s Respiratory Questionnaire (...
Autores principales: | Bongomin, Felix, Harris, Chris, Hayes, Gemma, Kosmidis, Chris, Denning, David W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892866/ https://www.ncbi.nlm.nih.gov/pubmed/29634721 http://dx.doi.org/10.1371/journal.pone.0193732 |
Ejemplares similares
-
Innate and Adaptive Immune Defects in Chronic Pulmonary Aspergillosis
por: Bongomin, Felix, et al.
Publicado: (2017) -
Chronic pulmonary aspergillosis following pulmonary embolism
por: Tunney, Ruth, et al.
Publicado: (2018) -
The clinical spectrum of aspergillosis in chronic obstructive pulmonary disease
por: Otu, Akaninyene, et al.
Publicado: (2023) -
The incidence of cutaneous squamous cell carcinoma in patients receiving voriconazole therapy for chronic pulmonary aspergillosis
por: Kosmidis, Chris, et al.
Publicado: (2020) -
Special Issue: Chronic Pulmonary Aspergillosis
por: Kosmidis, Chris
Publicado: (2022)